Abiopharma

Vir Biotechnology - Vir Biotechnology Announces AASLD The LiverMeeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile